Calidi Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.64 USD (Oct 30, 2026, 9:18 AM EDT) · Market cap 2.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as Ne...